ALHC vs UNH: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
UNH is the larger of the two ($308.55B market cap): the incumbent the market prices for continued execution (14.67x forward earnings, beta 0.52). ALHC is the smaller challenger ($1.38B), cheaper on forward earnings (11.91x): more room to run, but more to prove. On the numbers, ALHC leads on both counts: faster expected revenue growth (25% vs 3%) and a lower forward P/E (11.91x vs 14.67x). The case for UNH rests on its own driver (Optum growth engine): if you believe in that, UNH fits; if you believe in what the numbers show today, ALHC does.
ALHC vs UNH: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALHC | UNH | What it tells you |
|---|---|---|---|
| Market cap | $1.38B | $308.55B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.91 | 14.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 47.21 | 19.65 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.04 | 0.52 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 3% of range | 43% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.99 | 3.15 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ALHC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ALHC and UNH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALHC and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALHC and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alignment Healthcare (ALHC) do?
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving about 301,200 members as of the third quarter of 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings are central to the thesis because they drive bonus payments and help attract members, which is why the October 2026 release of 2027 ratings hit so hard: the share of Alignment's members in plans rated at least 4 stars fell from 98% in 2026 to 25% in 2027. Alignment has sued CMS in U.S. District Court for D.C., arguing the stars methodology was changed through technical notes rather than rulemaking, and its complaint says the drop will cost more than $200 million in 2028 payments.
What does UnitedHealth Group (UNH) do?
UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.
ALHC vs UNH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ALHC drivers: Membership growth engine; Margin and profitability inflection.
- UNH drivers: Optum growth engine; Medicare Advantage scale.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.
ALHC or UNH: which should you pick?
If the story you believe is ALHC's (Membership growth engine), ALHC is the more direct way to own it; if it is UNH's (Optum growth engine), UNH is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALHC and UNH guides.
ALHC vs UNH: the full fundamentals
ALHC. ALHC kept growing through 2026, yet the share price fell from a 52-week high near $25 to about $6.58 by November 20, 2026 after the 2027 Star Ratings drop and a Q3 that swung to a loss. The stock trades at under 0.3 times sales and about 12 times forward earnings, and the 12 analysts tracked by Yahoo Finance had a mean target near $10.79. The pending lawsuit against CMS and the trend in claims costs are the next markers.
UNH. The trailing P/E of about 19.7x is still inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 14.7x, down from about 17x in October as the share price fell about 18% in a month. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. Twenty-five analysts have a mean target near $476, well above the November 20 close, while HSBC sits at $385 and TD Cowen at $455.
Headline figures (approximate, November 2026): ALHC shows revenue (ttm) ~$4.94B, up ~37% YoY in the latest quarter, q3 2026 revenue ~$1.36B; adjusted EPS $0.05 vs $0.04 expected, net income (ttm) ~$29M (~0.6% net margin); Q3 net loss ~$8M, p/e ~47x trailing, ~12x forward; UNH shows revenue (ttm) ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year, operating margin ~5.8% (net margin ~3.5%), net income (ttm) ~$15.9 billion (sensitive to medical costs), eps ~$17.52 trailing; Q3 2026 $4.69 vs $4.14 consensus; Q4 consensus ~$2.28.
The bottom line: ALHC vs UNH
ALHC and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALHC and UNH exposure against your real portfolio. It is not an investment adviser.
Wondering how ALHC or UNH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alignment Healthcare
Ask Walnut's AI anything about ALHC and see how it fits what you own.
FAQ
What is the difference between ALHC and UNH?
+
Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving about 301,200 members as of the third quarter of 2026. UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALHC or UNH the better stock?
+
Neither is universally better. UNH is the larger incumbent; ALHC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALHC or UNH?
+
On forward P/E (as of November 2026), ALHC trades at 11.91x and UNH at 14.67x, so ALHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALHC and UNH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALHC vs UNH?
+
ALHC: The Star Ratings collapse is now the most concrete risk: if the lawsuit fails, lower 2027 ratings cut 2028 bonus payments by more than $200 million according to the complaint, and weaker ratings can make plans less attractive during enrollment. Medical costs have already moved against the company: Q3 2026 brought a net loss on higher catastrophic and skilled nursing costs and claims volatility after a systems migration, and margins are thin (about 0.6% net over the trailing twelve months). Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, risk coding and Medicare Advantage audits directly affects revenue and bonus payments. Sentiment has reset sharply: UBS cut its target to $9 from $22 in October 2026 and then to $8 after the Q3 report, and the 52-week low of about $6.01 sits near the current price. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits. UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. A proposed federal anti-fraud rule targeting Medicare Advantage is the newest policy risk; it knocked managed-care stocks lower in November 2026, and analysts at TD Cowen called it a potential headwind likely to face legal challenges. The 2026 recovery also raises the bar: even after the November drop, at roughly 14.7x forward earnings the stock prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALHC or UNH; figures are approximate and dated (as of November 2026). Verify current data before investing.